Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Burnett, J. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Burnett, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Nesiritide: new hope for acute heart failure syndromes?

John C. Burnett*

Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA

* Corresponding author. E-mail address: burnett.john{at}mayo.edu

B-type natriuretic peptide (BNP) is a peptide hormone that exerts cardiac, renal, and hormonal effects, and is produced by the myocardium as part of the compensatory response of the failing heart. The therapeutic benefits of exogenous BNP administration to patients with acute heart failure syndromes have been demonstrated, and recombinant human BNP (nesiritide) was licensed in the USA for the treatment of this condition in 2001. Recent studies have also found that the beneficial effects of BNP in patients with heart failure extend beyond haemodynamics, to include natriuretic, renoprotective, and anti-remodelling properties. New therapeutic opportunities for BNP are also under investigation, including the possibility of long-term use in patients with chronic congestive heart failure.

Key Words: Acute disease • B-type natriuretic peptide • Congestive heart failure • pathophysiology/prevention and control/therapy • Pharmacotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.